Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
114 patients diagnosed with probable (n = 65) or definite (n = 49) PNS between July 2016 and October 2024 were analyzed.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Age < 65 years, CNS involvement and immunotherapy are relevant to favorable short-term outcome. SCLC and high-risk antibodies are adverse factors of long-term survival in PNS.
[PURPOSE] To explore the clinical features, treatment, and prognosis of paraneoplastic neurological syndromes (PNS).
- 표본수 (n) 65
- p-value P = 0.005
- p-value P = 0.039
- 95% CI 1.45-7.98
- OR 3.41
- HR 3.04
- 연구 설계 cohort study
APA
Hu M, Wang Q, et al. (2025). Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China.. Frontiers in immunology, 16, 1715164. https://doi.org/10.3389/fimmu.2025.1715164
MLA
Hu M, et al.. "Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China.." Frontiers in immunology, vol. 16, 2025, pp. 1715164.
PMID
41573575
Abstract
[PURPOSE] To explore the clinical features, treatment, and prognosis of paraneoplastic neurological syndromes (PNS).
[METHODS] In this retrospective cohort study, the records of 114 patients diagnosed with probable (n = 65) or definite (n = 49) PNS between July 2016 and October 2024 were analyzed. Short-term outcome was defined as the point decrease in modified Rankin Scale score from peak disease to discharge(Δmodified Rankin Scale). Long-term prognosis was determined by mortality at last follow-up. Prognostic factors were identified using logistic regression and Cox models. The impact of tumors and high-risk antibodies on survival were assessed by Kaplan-Meier curves.
[RESULTS] Of the 114 patients, 65 (57.0%) were males. The median age was 63 years. Muscle weakness (53.5%) was most common, followed by seizures and altered consciousness. Associated tumors occurred in 66.7% of patients, mainly lung (65.8%) and breast cancer (9.2%). Antibodies were detected in 79.8%, including (single and multiple antibody types) anti-GABAR (24.2%), anti-Hu (19.8%), and anti-SOX1 (19.8%). Multiple antibodies were detected in 18.4%, including anti-Hu plus anti-SOX1 (19.0%), anti-SOX1 plus anti-GABAR (14.3%), and others. Independent factors associated with short-term favorable outcome (Δmodified Rankin Scale ≥1) were age < 65 years(OR = 3.41, 95% CI: 1.45-7.98, P = 0.005), CNS involvement (OR = 2.46, 95% CI: 1.05-5.80, P = 0.039), and immunotherapy (OR = 5.12, 95% CI: 1.70-15.42, P = 0.004). The median survival was 32 months (IQR, 12-106), the 3-year survival rate was 45.8%. SCLC (HR = 3.04, 95% CI: 1.71-5.41, P < 0.001) and high-risk antibodies (HR = 2.06, 95% CI: 1.17-3.62, P = 0.012) were independently associated with higher mortality.
[CONCLUSIONS] Age < 65 years, CNS involvement and immunotherapy are relevant to favorable short-term outcome. SCLC and high-risk antibodies are adverse factors of long-term survival in PNS.
[METHODS] In this retrospective cohort study, the records of 114 patients diagnosed with probable (n = 65) or definite (n = 49) PNS between July 2016 and October 2024 were analyzed. Short-term outcome was defined as the point decrease in modified Rankin Scale score from peak disease to discharge(Δmodified Rankin Scale). Long-term prognosis was determined by mortality at last follow-up. Prognostic factors were identified using logistic regression and Cox models. The impact of tumors and high-risk antibodies on survival were assessed by Kaplan-Meier curves.
[RESULTS] Of the 114 patients, 65 (57.0%) were males. The median age was 63 years. Muscle weakness (53.5%) was most common, followed by seizures and altered consciousness. Associated tumors occurred in 66.7% of patients, mainly lung (65.8%) and breast cancer (9.2%). Antibodies were detected in 79.8%, including (single and multiple antibody types) anti-GABAR (24.2%), anti-Hu (19.8%), and anti-SOX1 (19.8%). Multiple antibodies were detected in 18.4%, including anti-Hu plus anti-SOX1 (19.0%), anti-SOX1 plus anti-GABAR (14.3%), and others. Independent factors associated with short-term favorable outcome (Δmodified Rankin Scale ≥1) were age < 65 years(OR = 3.41, 95% CI: 1.45-7.98, P = 0.005), CNS involvement (OR = 2.46, 95% CI: 1.05-5.80, P = 0.039), and immunotherapy (OR = 5.12, 95% CI: 1.70-15.42, P = 0.004). The median survival was 32 months (IQR, 12-106), the 3-year survival rate was 45.8%. SCLC (HR = 3.04, 95% CI: 1.71-5.41, P < 0.001) and high-risk antibodies (HR = 2.06, 95% CI: 1.17-3.62, P = 0.012) were independently associated with higher mortality.
[CONCLUSIONS] Age < 65 years, CNS involvement and immunotherapy are relevant to favorable short-term outcome. SCLC and high-risk antibodies are adverse factors of long-term survival in PNS.
MeSH Terms
Humans; Male; Female; Middle Aged; China; Prognosis; Aged; Retrospective Studies; Adult; Autoantibodies; Paraneoplastic Syndromes, Nervous System; Aged, 80 and over; Paraneoplastic Syndromes
같은 제1저자의 인용 많은 논문 (5)
- Commentary on Multimodal profiling identifies CD4+CXCR5+PD-1-Tfh cells as prognostic and predictive biomarkers in diffuse large B-cell lymphoma.
- A Comparative Study of Computed Tomography-Guided Steerable Needle and Freehand Biopsy for Diagnosing Small Pulmonary Nodules: Accuracy and Complications for Greater Clarity and Precision.
- Single-cell transcriptomics uncover RNF130-mediated TNF-α pathway activation and worenine synergy with paclitaxel in breast cancer.
- From 3D culture to clinical decision-making: Systematic innovations in breast cancer organoids.
- GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARγ pathway to drive M2 macrophage polarization.